Compare MXCT & QTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MXCT | QTRX |
|---|---|---|
| Founded | 1999 | 2007 |
| Country | United States | United States |
| Employees | 91 | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.0M | 160.0M |
| IPO Year | 2021 | 2017 |
| Metric | MXCT | QTRX |
|---|---|---|
| Price | $1.24 | $4.32 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 2 |
| Target Price | $5.50 | ★ $6.00 |
| AVG Volume (30 Days) | 932.0K | ★ 1.2M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $33,026,000.00 | ★ $37,632,000.00 |
| Revenue This Year | N/A | $25.49 |
| Revenue Next Year | $18.50 | $10.04 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 64.52 |
| 52 Week Low | $0.64 | $2.40 |
| 52 Week High | $2.37 | $8.77 |
| Indicator | MXCT | QTRX |
|---|---|---|
| Relative Strength Index (RSI) | 65.10 | 67.91 |
| Support Level | $0.77 | $2.98 |
| Resistance Level | $1.30 | $6.27 |
| Average True Range (ATR) | 0.07 | 0.34 |
| MACD | 0.00 | 0.10 |
| Stochastic Oscillator | 68.00 | 98.91 |
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
Quanterix Corp is a life sciences company accelerating biomarker breakthroughs from discovery to diagnostics using ultra-sensitive translational research and spatial biology instruments, consumables, and services. The company sells proprietary instruments and related consumables to research laboratories, contract research organizations (CROs), academic institutions, and bio-pharmaceutical companies, and provides contract research services and clinical laboratory testing services, including four Laboratory Developed Tests (LDTs), through its Accelerator Laboratory. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, and SP-X Imaging and Analysis System. Geographically, it operates in North America, EMEA, and the Asia Pacific.